Coherus BioSciences (NASDAQ:CHRS – Get Free Report) and Quantum Genomics Société Anonyme (OTCMKTS:QNNTF – Get Free Report) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, valuation, earnings and risk.
Analyst Recommendations
This is a breakdown of current recommendations for Coherus BioSciences and Quantum Genomics Société Anonyme, as reported by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Coherus BioSciences | 0 | 1 | 3 | 0 | 2.75 |
Quantum Genomics Société Anonyme | 0 | 0 | 0 | 0 | 0.00 |
Coherus BioSciences presently has a consensus target price of $5.38, indicating a potential upside of 486.98%. Given Coherus BioSciences’ stronger consensus rating and higher probable upside, research analysts plainly believe Coherus BioSciences is more favorable than Quantum Genomics Société Anonyme.
Earnings & Valuation
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Coherus BioSciences | $266.96 million | 0.40 | -$237.89 million | $0.19 | 4.82 |
Quantum Genomics Société Anonyme | N/A | N/A | N/A | N/A | N/A |
Quantum Genomics Société Anonyme has lower revenue, but higher earnings than Coherus BioSciences.
Risk and Volatility
Coherus BioSciences has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500. Comparatively, Quantum Genomics Société Anonyme has a beta of 0.22, indicating that its stock price is 78% less volatile than the S&P 500.
Institutional and Insider Ownership
72.8% of Coherus BioSciences shares are owned by institutional investors. 7.6% of Coherus BioSciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Profitability
This table compares Coherus BioSciences and Quantum Genomics Société Anonyme’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Coherus BioSciences | -0.15% | N/A | -24.44% |
Quantum Genomics Société Anonyme | N/A | N/A | N/A |
Summary
Coherus BioSciences beats Quantum Genomics Société Anonyme on 7 of the 9 factors compared between the two stocks.
About Coherus BioSciences
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company’s licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
About Quantum Genomics Société Anonyme
Quantum Genomics Société Anonyme, a biopharmaceutical company, engages in the development of drugs to treat cardiovascular diseases. The company develops its drugs based on brain inhibition mechanism of Aminopeptidase A: BAPAI, a triple-action therapeutic platform primarily to treat high blood pressure and heart failure. It is developing firibastat, a treatment for high blood pressure, and in combination with others anti-hypertensive drugs. The company also is involved in the development of drugs for the treatment of high blood pressure as monotherapy and the prevention, as well as treatment of heart failure. Quantum Genomics Société Anonyme was incorporated in 2005 and is based in Paris, France.
Receive News & Ratings for Coherus BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.